References
- Nishimura RA , Otto CM , Bonow RO , et al. AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol . 2017;70:252–289. doi:10.1016/j.jacc.2017.03.011.
- Zilberszac R , Gabriel H , Schemper M , et al. Outcome of combined stenotic and regurgitant aortic valve disease. J Am Coll Cardiol . 2013;61:1489–1495. doi:10.1016/j.jacc.2012.11.070.
- Egbe AC , Poterucha JT , Warnes CA. Mixed aortic valve disease: midterm outcome and predictors of adverse events. Eur Heart J . 2016;37:2671–2678. doi:10.1093/eurheartj/ehw079.
- Andell P , Li X , Martinsson A , et al. Epidemiology of valvular heart disease in a Swedish nationwide hospital-based register study. Heart . 2017;103:1696–1703. doi:10.1136/heartjnl-2016-310894.
- Sorajja P, Nelson P, Garberich R, Bradley SM, Athappan G, Bae R, Harris K, Lesser J, Tindell L, Farivar RS, Goessl M. Clinical Impact of Chronic Aortic Regurgitation in Asymptomatic Patients with Native Aortic Valve Stenosis. Struct Heart . 2018; this issue. doi:10.1080/24748706.2018.1479078.